S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
66,000% upside on tiny biotech? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:ZYNE

Zynerba Pharmaceuticals (ZYNE) Stock Forecast, Price & News

$0.34
+0.02 (+6.25%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.32
▼
$0.34
50-Day Range
$0.30
▼
$0.44
52-Week Range
$0.30
▼
$1.60
Volume
193,848 shs
Average Volume
220,253 shs
Market Capitalization
$18.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Zynerba Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
3,135.3% Upside
$11.00 Price Target
Short Interest
Healthy
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.78) to ($0.61) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

467th out of 983 stocks

Pharmaceutical Preparations Industry

222nd out of 486 stocks

See Top Rated MarketRank™ Stocks Here

ZYNE stock logo

About Zynerba Pharmaceuticals (NASDAQ:ZYNE) Stock

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Stock News Headlines

May 31, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Research Coverage Started at StockNews.com
May 24, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Now Covered by StockNews.com
June 4, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 23, 2023 | americanbankingnews.com
FY2023 Earnings Forecast for Zynerba Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:ZYNE)
May 17, 2023 | bizjournals.com
Main Line CBD drug developer plans reverse stock split to boost share price
May 17, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Issues Earnings Results
May 15, 2023 | finanznachrichten.de
Zynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023 | investing.com
Zynerba Pharma (ZYNE) Earnings Dates & Reports
June 4, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 15, 2023 | msn.com
Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details
May 15, 2023 | finance.yahoo.com
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023 | finance.yahoo.com
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Receives New Coverage from Analysts at StockNews.com
May 13, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest Down 49.6% in April
May 7, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Now Covered by Analysts at StockNews.com
April 30, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Coverage Initiated at StockNews.com
April 18, 2023 | marketwatch.com
Fibromyalgia Treatment Drug Market Overview and Scope By 2030
April 18, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest Update
April 14, 2023 | marketwatch.com
Zynerba Pharmaceuticals Presents Data on Zygel(TM) at the 55th Gatlinburg Conference
April 13, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Zynerba Pharmaceuticals (NASDAQ:ZYNE)
April 12, 2023 | finance.yahoo.com
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
April 5, 2023 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
April 4, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Boosted by Jefferies Financial Group
March 31, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Announces Earnings Results
March 31, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to Post Q1 2024 Earnings of ($0.22) Per Share, Jefferies Financial Group Forecasts
March 30, 2023 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS
March 28, 2023 | finanznachrichten.de
Zynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
See More Headlines

ZYNE Price History

ZYNE Company Calendar

Last Earnings
5/15/2023
Today
6/03/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZYNE
CUSIP
N/A
CIK
1621443
Web
www.zynerba.com
Phone
(484) 581-7505
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+3,135.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,040,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-75.12%
Return on Assets
-62.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.95
Quick Ratio
4.95

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.73 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
53,652,000
Free Float
46,656,000
Market Cap
$18.24 million
Optionable
Optionable
Beta
1.73

Key Executives

  • Armando Anido
    Chairman & Chief Executive Officer
  • Terri B. Sebree
    President
  • James E. Fickenscher
    Chief Financial Officer & VP-Corporate Development
  • Nancy Tich
    Vice President-Clinical
  • Stephen O'Quinn
    Vice President-Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ZYNE Stock - Frequently Asked Questions

Should I buy or sell Zynerba Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYNE shares.
View ZYNE analyst ratings or view top-rated stocks.

What is Zynerba Pharmaceuticals' stock price forecast for 2023?

4 brokerages have issued twelve-month price targets for Zynerba Pharmaceuticals' shares. Their ZYNE share price forecasts range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 3,135.3% from the stock's current price.
View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts.

How have ZYNE shares performed in 2023?

Zynerba Pharmaceuticals' stock was trading at $0.53 on January 1st, 2023. Since then, ZYNE stock has decreased by 35.8% and is now trading at $0.34.
View the best growth stocks for 2023 here.

When is Zynerba Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ZYNE earnings forecast.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02.

What ETFs hold Zynerba Pharmaceuticals' stock?

ETFs with the largest weight of Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock in their portfolio include Amplify Growth Opportunities ETF (CNBS).ETFMG Alternative Harvest ETF (MJ).

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include ETF Managers Group LLC (1.36%), Renaissance Technologies LLC (1.06%) and Two Sigma Advisers LP (0.27%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher and Terri B Sebree.
View institutional ownership trends.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $0.34.

How much money does Zynerba Pharmaceuticals make?

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $18.24 million. The company earns $-35,040,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com.

This page (NASDAQ:ZYNE) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -